Treatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report (Q89700420)

From Wikidata

Jump to navigation Jump to search

scientific article published on 11 March 2016

Language	Label	Description	Also known as
English	Treatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report	scientific article published on 11 March 2016

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29263894%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

Treatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report (English)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29263894%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

non-Hodgkin lymphoma

1 reference

based on heuristic

inferred from title

B-cell non-Hodgkin lymphoma

1 reference

based on heuristic

inferred from title

author name string

Wen-Ying Zhang

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29263894%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

Yao Wang

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29263894%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

Ye-Lei Guo

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29263894%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

Han-Ren Dai

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29263894%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

Qing-Ming Yang

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29263894%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

Ya-Jing Zhang

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29263894%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

Yan Zhang

7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29263894%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

Mei-Xia Chen

8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29263894%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

Chun-Meng Wang

9

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29263894%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

Kai-Chao Feng

10

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29263894%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

Su-Xia Li

11

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29263894%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

Yang Liu

12

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29263894%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

Feng-Xia Shi

13

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29263894%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

Can Luo

14

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29263894%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

Wei-Dong Han

15

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29263894%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

publication date

11 March 2016

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29263894%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29263894%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

16002

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29263894%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

copyright license

Creative Commons Attribution 4.0 International

11 March 2016

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FSIGTRANS.2016.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

1 reference

https://api.crossref.org/works/10.1038%2FSIGTRANS.2016.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSIGTRANS.2016.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSIGTRANS.2016.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSIGTRANS.2016.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study.

1 reference

https://api.crossref.org/works/10.1038%2FSIGTRANS.2016.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSIGTRANS.2016.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FSIGTRANS.2016.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Immune surveillance of tumors

1 reference

https://api.crossref.org/works/10.1038%2FSIGTRANS.2016.2

7 January 2021

based on heuristic

inferred from DOI database lookup

An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSIGTRANS.2016.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Adoptive immunotherapy for cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSIGTRANS.2016.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Video podcast: Adoptive immunotherapy for cancer

1 reference

https://api.crossref.org/works/10.1038%2FSIGTRANS.2016.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells

1 reference

https://api.crossref.org/works/10.1038%2FSIGTRANS.2016.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor

1 reference

https://api.crossref.org/works/10.1038%2FSIGTRANS.2016.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells

1 reference

https://api.crossref.org/works/10.1038%2FSIGTRANS.2016.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1038%2FSIGTRANS.2016.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Importance of antigen specificity for complement-mediated lysis by monoclonal antibodies.

1 reference

https://api.crossref.org/works/10.1038%2FSIGTRANS.2016.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

1 reference

https://api.crossref.org/works/10.1038%2FSIGTRANS.2016.2

7 January 2021

based on heuristic

inferred from DOI database lookup

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSIGTRANS.2016.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSIGTRANS.2016.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Managing cytokine release syndrome associated with novel T cell-engaging therapies.

1 reference

https://api.crossref.org/works/10.1038%2FSIGTRANS.2016.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells

1 reference

https://api.crossref.org/works/10.1038%2FSIGTRANS.2016.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

1 reference

https://api.crossref.org/works/10.1038%2FSIGTRANS.2016.2

7 January 2021

based on heuristic

inferred from DOI database lookup

CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients

1 reference

https://api.crossref.org/works/10.1038%2FSIGTRANS.2016.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSIGTRANS.2016.2

7 January 2021

based on heuristic

inferred from DOI database lookup

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

1 reference

https://api.crossref.org/works/10.1038%2FSIGTRANS.2016.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19

1 reference

https://api.crossref.org/works/10.1038%2FSIGTRANS.2016.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies.

1 reference

https://api.crossref.org/works/10.1038%2FSIGTRANS.2016.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy?

1 reference

https://api.crossref.org/works/10.1038%2FSIGTRANS.2016.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice

1 reference

https://api.crossref.org/works/10.1038%2FSIGTRANS.2016.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSIGTRANS.2016.2

7 January 2021

based on heuristic

inferred from DOI database lookup

CD5- and CD23-positive splenic diffuse large B-cell lymphoma with very low CD20 expression

1 reference

https://api.crossref.org/works/10.1038%2FSIGTRANS.2016.2

7 January 2021

based on heuristic

inferred from DOI database lookup

[Impact of chemotherapies on immunosuppression and discovery of new therapeutic targets]

1 reference

https://api.crossref.org/works/10.1038%2FSIGTRANS.2016.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Organ-specific migration of mesenchymal stromal cells: Who, when, where and why?

1 reference

https://api.crossref.org/works/10.1038%2FSIGTRANS.2016.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Prerequisites for the antitumor vaccine-like effect of chemotherapy and radiotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSIGTRANS.2016.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of radiotherapy in 153 primary cutaneous B-Cell lymphomas classified according to the WHO-EORTC classification

1 reference

https://api.crossref.org/works/10.1038%2FSIGTRANS.2016.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSIGTRANS.2016.2

7 January 2021

based on heuristic

inferred from DOI database lookup

External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing

1 reference

https://api.crossref.org/works/10.1038%2FSIGTRANS.2016.2

7 January 2021

based on heuristic

inferred from DOI database lookup

PD-1 blockade induces responses by inhibiting adaptive immune resistance

1 reference

https://api.crossref.org/works/10.1038%2FSIGTRANS.2016.2

7 January 2021

based on heuristic

inferred from DOI database lookup

CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSIGTRANS.2016.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29263894

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29263894

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/SIGTRANS.2016.2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29263894%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29263894%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29263894%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q89700420&oldid=1853306182"